Clark Estates Inc. NY Boosts Position in Avanos Medical, Inc. $AVNS

Clark Estates Inc. NY increased its position in shares of Avanos Medical, Inc. (NYSE:AVNS) by 58.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 783,880 shares of the company’s stock after acquiring an additional 290,000 shares during the quarter. Avanos Medical makes up about 2.1% of Clark Estates Inc. NY’s portfolio, making the stock its 14th biggest holding. Clark Estates Inc. NY owned approximately 1.69% of Avanos Medical worth $9,062,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Armistice Capital LLC lifted its holdings in Avanos Medical by 1.8% in the second quarter. Armistice Capital LLC now owns 2,036,000 shares of the company’s stock valued at $24,921,000 after acquiring an additional 36,000 shares during the last quarter. Qube Research & Technologies Ltd raised its position in Avanos Medical by 32.5% in the second quarter. Qube Research & Technologies Ltd now owns 625,409 shares of the company’s stock valued at $7,655,000 after purchasing an additional 153,547 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Avanos Medical by 116.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 577,889 shares of the company’s stock valued at $6,680,000 after purchasing an additional 311,317 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Avanos Medical by 190.4% during the 2nd quarter. AQR Capital Management LLC now owns 560,052 shares of the company’s stock worth $6,855,000 after purchasing an additional 367,188 shares during the period. Finally, Millennium Management LLC increased its position in shares of Avanos Medical by 508.3% during the 1st quarter. Millennium Management LLC now owns 547,740 shares of the company’s stock worth $7,849,000 after purchasing an additional 457,703 shares during the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Avanos Medical Stock Performance

NYSE:AVNS opened at $15.47 on Monday. Avanos Medical, Inc. has a 52 week low of $9.30 and a 52 week high of $16.63. The company has a fifty day simple moving average of $12.79 and a two-hundred day simple moving average of $11.99. The company has a quick ratio of 1.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.12. The company has a market cap of $718.02 million, a price-to-earnings ratio of -1.52 and a beta of 1.09.

Analysts Set New Price Targets

A number of brokerages have weighed in on AVNS. Wall Street Zen upgraded shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Zacks Research upgraded shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Reduce”.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.